Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease

Discontinuation of anti–tumor necrosis factor-α treatment (anti-TNF) (infliximab and adalimumab) in patients with inflammatory bowel disease (IBD) is associated with a high relapse risk that may be influenced by endoscopic activity at the time of stopping. We assessed the relapse rate after anti-TNF...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical gastroenterology and hepatology 2023-03, Vol.21 (3), p.750-760.e4
Hauptverfasser:	Mahmoud, Remi, Savelkoul, Edo H.J., Mares, Wout, Goetgebuer, Rogier, Witteman, Ben J.M., de Koning, Daan B., van Tuyl, Sebastiaan A.C., Minderhoud, Itta, Lutgens, Maurice W.M. D., Akol-Simsek, Dilek, van Schaik, Fiona D.M., Fidder, Herma H., Jansen, Jeroen M., van Boeckel, Petra G.A., Mahmmod, Nofel, Horjus-Talabur Horje, Carmen S., Römkens, Tessa E.H., Colombel, Jean-Frédéric, Hoentjen, Frank, Jharap, Bindia, Oldenburg, Bas
Format:	Artikel
Sprache:	eng
Schlagworte:	Biologicals De-escalation Deep Remission Endoscopic Remission
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Discontinuation of anti–tumor necrosis factor-α treatment (anti-TNF) (infliximab and adalimumab) in patients with inflammatory bowel disease (IBD) is associated with a high relapse risk that may be influenced by endoscopic activity at the time of stopping. We assessed the relapse rate after anti-TNF withdrawal in patients with endoscopic healing and studied predictors of relapse including the depth of endoscopic healing. This was a multicenter, prospective study in adult patients with Crohn’s disease (CD), ulcerative colitis (UC), or IBD-unclassified (IBDU), with ≥6 months of corticosteroid-free clinical remission (confirmed at baseline) and endoscopic healing (Mayo
ISSN:	1542-3565 1542-7714
DOI:	10.1016/j.cgh.2022.08.024